Evaluation and management of patients with pulmonary nontuberculous mycobacterial infections

References

• Ichiyama S, Shimokata K, Tsukamura M. The isolation of Mycobacterium avium complex from soil, water, and dusts. Microbiol. Immunol.32(7), 733–739 (1988).
   PubMedGoogle Scholar
• du Moulin GC, Stottmeier KD, Pelletier PA, Tsang AY, Hedley-Whyte J. Concentration of Mycobacterium avium by hospital hot water systems. JAMA260(11), 1599–1601 (1988).
   PubMed Web of Science ®Google Scholar
• Von Reyn CF, Arbeit RD, Horsburgh CR et al. Sources of disseminated Mycobacterium avium infection in AIDS. J. Infect.44(3), 166–170 (2002).
   PubMed Web of Science ®Google Scholar
• Aubry A, Chosidow O, Caumes E, Robert J, Cambau E. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch. Intern. Med.162(15), 1746–1752 (2002).
   PubMed Web of Science ®Google Scholar
• Runyon EH. Typical myobacteria: their classification. Am. Rev. Respir. Dis.91, 288–289 (1965).
   PubMedGoogle Scholar
• Leitritz L, Schubert S, Bucherl B et al. Evaluation of BACTEC MGIT 960 and BACTEC 460TB systems for recovery of mycobacteria from clinical specimens of a university hospital with low incidence of tuberculosis. J. Clin. Microbiol.39(10), 3764–3767 (2001).
   PubMedGoogle Scholar
• Cloud JL, Neal H, Rosenberry R et al. Identification of Mycobacterium spp. by using a commercial 16S ribosomal DNA sequencing kit and additional sequencing libraries. J. Clin. Microbiol.40(2), 400–406 (2002).
   PubMedGoogle Scholar
• Cook VJ, Turenne CY, Wolfe J, Pauls R, Kabani A. Conventional methods versus 16S ribosomal DNA sequencing for identification of nontuberculous mycobacteria: cost analysis. J. Clin. Microbiol.41(3), 1010–1015 (2003).
   PubMedGoogle Scholar
• Cloud JL, Hoggan K, Belousov E et al. Use of the MGB Eclipse system and SmartCycler PCR for differentiation of Mycobacterium chelonae and M. abscessus. J. Clin. Microbiol.43(8), 4205–4207 (2005).
   PubMedGoogle Scholar
• Runyon EH. Anonymous mycobacteria in pulmonary disease. Med. Clin. North Am.43, 273–290 (1959).
   PubMed Web of Science ®Google Scholar
• Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am. Rev. Respir. Dis.119(1), 107–159 (1979).
   PubMed Web of Science ®Google Scholar
• Lewis AG Jr, Lasche EM, Armstrong AL, Dunbar FP. A clinical study of the chronic lung disease due to nonphotochromogenic acid-fast bacilli. Ann. Intern. Med.53, 273–285 (1960).
   PubMed Web of Science ®Google Scholar
• Bates JH. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: Clinical characteristics. Am. Rev. Respir. Dis.96, 1151–1157 (1967).
   PubMed Web of Science ®Google Scholar
• Kim TC, Arora NS, Aldrich TK, Rochester DF. Atypical mycobacterial infections: a clinical study of 92 patients. South. Med. J.74(11), 1304–1308 (1981).
   PubMedGoogle Scholar
• Rosenzweig DY and Schlueter DP. Spectrum of clinical disease in pulmonary infection with Mycobacterium avium-intracellulare. Rev. Infect. Dis.3(5), 1046–1051 (1981).
   PubMedGoogle Scholar
• Engbaek HC, Vergmann B, Bentzon MW. Lung disease caused by Mycobacterium avium/Mycobacterium intracellulare. An analysis of Danish patients during the period 1962–1976. Eur. J. Respir. Dis.62(2), 72–83 (1981).
   PubMedGoogle Scholar
• Kwon YS, Koh WJ, Kwon OJ et al. Mycobacterium abscessus pulmonary infection presenting as a solitary pulmonary nodule. Intern. Med45(3), 169–171 (2006).
   PubMedGoogle Scholar
• Kobashi Y, Yoshida K, Miyashita N, Niki Y, Matsushima T. Pulmonary Mycobacterium avium disease with a solitary pulmonary nodule requiring differentiation from recurrence of pulmonary adenocarcinoma. Intern. Med43(9), 855–860 (2004).
   PubMedGoogle Scholar
• Marchevsky A, Damsker B, Gribetz A, Tepper S, Geller SA. The spectrum of pathology of nontuberculous mycobacterial infections in open-lung biopsy specimens. Am. J. Clin. Pathol.78(5), 695–700 (1982).
   PubMedGoogle Scholar
• Costrini AM, Mahler DA, Gross WM et al. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am. Rev. Respir. Dis.123(1), 104–109 (1981).
   PubMed Web of Science ®Google Scholar
• Prince DS, Peterson DD, Steiner RM et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N. Engl. J. Med.321(13), 863–868 (1989).
   PubMed Web of Science ®Google Scholar
• Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest115(4), 1033–1040 (1999).
   PubMed Web of Science ®Google Scholar
• Watanabe K, Fujimura M, Kasahara K et al. Characteristics of pulmonary Mycobacterium avium-intracellulare complex (MAC) infection in comparison with those of tuberculosis. Respir. Med.97(6), 654–659 (2003).
   PubMedGoogle Scholar
• Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am. Rev. Respir. Dis.147(5), 1271–1278 (1993).
   PubMed Web of Science ®Google Scholar
• Olivier KN, Weber DJ, Wallace RJ Jr et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am. J. Respir. Crit. Care Med.167, 828–834 (2003).
   PubMed Web of Science ®Google Scholar
• Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J. Clin. Microbiol.43(7), 3467–3470 (2005).
   PubMedGoogle Scholar
• Olivier KN, Weber DJ, Lee JH et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med.167(6), 835–840 (2003).
   PubMed Web of Science ®Google Scholar
• Marras TK, Wallace RJ, Jr., Koth LL et al. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest127(2), 664–671 (2005).
   PubMed Web of Science ®Google Scholar
• Hanak V, Kalra S, Aksamit TR et al. Hot tub lung: presenting features and clinical course of 21 patients. Respir. Med.100(4), 610–615 (2006).
   PubMedGoogle Scholar
• Wallace JR Jr, Zhang Y, Wilson RW, Mann L, Rossmoore H. Presence of a single genotype of the newly described species Mycobacterium immunogenum in industrial metalworking fluids associated with hypersensitivity pneumonitis. Appl. Environ. Microbiol.68(11), 5580–5584 (2002).
   PubMed Web of Science ®Google Scholar
• British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax55(3), 210–218 (2000).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med.156(2 Pt 2), S1–S25 (1997).
   PubMedGoogle Scholar
• Kennedy TP and Weber DJ. Nontuberculous mycobacteria. An underappreciated cause of geriatric lung disease. Am. J. Respir. Crit. Care Med.149(6), 1654–1658 (1994).
   PubMedGoogle Scholar
• Tanaka E, Amitani R, Niimi A et al. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am. J. Respir. Crit. Care Med.155(6), 2041–2046 (1997).
   PubMed Web of Science ®Google Scholar
• Lynch DA, Simone PM, Fox MA, Bucher BL, Heinig MJ. CT features of pulmonary Mycobacterium avium complex infection. J. Comput. Assist. Tomogr.19(3), 353–360 (1995).
   PubMedGoogle Scholar
• Swensen SJ, Hartman TE, Williams DE. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest105(1), 49–52 (1994).
   PubMed Web of Science ®Google Scholar
• Primack SL, Logan PM, Hartman TE, Lee KS, Muller NL. Pulmonary tuberculosis and Mycobacterium avium-intracellulare: a comparison of CT findings. Radiology194(2), 413–417 (1995).
   PubMed Web of Science ®Google Scholar
• Koh WJ, Lee KS, Kwon OJ et al. Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection. Radiology235(1), 282–288 (2005).
   PubMed Web of Science ®Google Scholar
• Von Reyn CF, Horsburgh CR, Olivier KN et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int. J. Tuberc. Lung Dis.5(12), 1122–1128 (2001).
   PubMed Web of Science ®Google Scholar
• Bierrenbach AL, Cunha SS, Barreto ML, Pereira SM, Rodrigues LC. Skin test reactivity to mycobacterial antigens parallels the phylogenetic structure of their genus. Int. J. Tuberc. Lung Dis.5(7), 656–663 (2001).
   PubMedGoogle Scholar
• Pai M, Riley LW, Colford JM Jr. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis.4(12), 761–776 (2004).
   PubMed Web of Science ®Google Scholar
• Vankayalapati R, Wizel B, Samten B et al. Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex. J. Infect. Dis.183(3), 478–484, (2001).
   PubMed Web of Science ®Google Scholar
• Kitada S, Maekura R, Toyoshima N et al. Serodiagnosis of pulmonary disease due to Mycobacterium avium complex with an enzyme immunoassay that uses a mixture of glycopeptidolipid antigens. Clin. Infect. Dis.35(11), 1328–1335 (2002).
   PubMed Web of Science ®Google Scholar
• Ferroni A, Sermet-Gaudelus I, Le Bourgeois M et al. Measurement of immunoglobulin G against mycobacterial antigen A60 in patients with cystic fibrosis and lung infection due to Mycobacterium abscessus. Clin. Infect. Dis.40(1), 58–66 (2005).
   PubMedGoogle Scholar
• Maugein J, Dailloux M, Carbonnelle B, Vincent V, Grosset J. Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease. Eur. Respir. J.26(6), 1092–1096 (2005).
   PubMedGoogle Scholar
• Kanathur N, Shantaveerapa HN, Byrd RP Jr, Mehta JB, Roy TM. Nontubercular mycobacterial pulmonary infection in immunocompetent men. South. Med. J.94(7), 719–723, (2001).
   PubMedGoogle Scholar
• Kubo K, Yamazaki Y, Hachiya T et al. Mycobacterium avium-intracellulare pulmonary infection in patients without known predisposing lung disease. Lung176(6), 381–391 (1998).
   PubMed Web of Science ®Google Scholar
• Daley CL and Griffith DE. Pulmonary disease caused by rapidly growing mycobacteria. Clin. Chest Med.23(3), 623–632, vii (2002).
   PubMedGoogle Scholar
• Maliwan N and Zvetina JR. Clinical features and follow up of 302 patients with Mycobacterium kansasii pulmonary infection: a 50 year experience. Postgrad. Med. J.81(958), 530–533 (2005).
   PubMed Web of Science ®Google Scholar
• Shitrit D, Baum GL, Priess R et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999–2004: clinical features, drug susceptibility, and outcome. Chest129(3), 771–776 (2006).
   PubMed Web of Science ®Google Scholar
• Contreras MA, Cheung OT, Sanders DE, Goldstein RS. Pulmonary infection with nontuberculous mycobacteria. Am. Rev. Respir. Dis.137(1), 149–152 (1988).
   PubMed Web of Science ®Google Scholar
• Rosenzweig DY. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest75(2), 115–119 (1979).
   PubMedGoogle Scholar
• Chbeir E, Casas L, Toubia N, Tawk M, Brown B. Adult cystic fibrosis presenting with recurrent non-tuberculous mycobacterial infections. Lancet367(9526), 1952 (2006).
   PubMedGoogle Scholar
• Wickremasinghe M, Ozerovitch LJ, Davies G et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax60(12), 1045–1051 (2005).
   PubMed Web of Science ®Google Scholar
• Francis PB, Jay SJ, Johanson WG Jr. The course of untreated Mycobacterium kansasii disease. Am. Rev. Respir. Dis.111(4), 477–487 (1975).
   PubMed Web of Science ®Google Scholar
• Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease. Incidence, presentation, and response to therapy in a community setting. Am. Rev. Respir. Dis.143(6), 1381–1385 (1991).
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Brown BA, Griffith DE et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am. J. Respir. Crit. Care Med.149(5), 1335–1341 (1994).
   PubMed Web of Science ®Google Scholar
• Woods GL, Williams-Bouyer N, Wallace RJ Jr et al. Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex. J. Clin. Microbiol.41(2), 627–631 (2003).
   PubMedGoogle Scholar
• Pezzia W, Raleigh JW, Bailey MC, Toth EA, Silverblatt J. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev. Infect. Dis.3(5), 1035–1039 (1981).
   PubMedGoogle Scholar
• Woods GL. Susceptibility testing for mycobacteria. Clin. Infect. Dis.31(5), 1209–1215 (2000).
   PubMed Web of Science ®Google Scholar
• Sauret J, Hernandez-Flix S, Castro E et al. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months’ chemotherapy. Tuber. Lung Dis.76(2), 104–108 (1995).
   PubMedGoogle Scholar
• Ahn CH, Lowell JR, Ahn SS, Ahn SI, Hurst GA. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am. Rev. Respir. Dis.128(6), 1048–1050 (1983).
   PubMed Web of Science ®Google Scholar
• British Thoracic Society. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax49(5), 442–445 (1994).
   PubMed Web of Science ®Google Scholar
• Guna R, Munoz C, Dominguez V et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J. Antimicrob. Chemother.55(6), 950–953 (2005).
   PubMedGoogle Scholar
• Griffith DE, Brown-Elliott BA, Wallace RJ Jr. thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin. Infect. Dis.37(9), 1178–1182 (2003).
   PubMed Web of Science ®Google Scholar
• Chatte G, Panteix G, Perrin-Fayolle M, Pacheco Y. Aerosolized interferon γ for Mycobacterium avium-complex lung disease. Am. J. Respir. Crit. Care Med.152(3), 1094–1096 (1995).
   PubMedGoogle Scholar
• Lam PK, Griffith DE, Aksamit TR et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med.173(11), 1283–1289 (2006).
   PubMed Web of Science ®Google Scholar
• Fujikane T, Fujiuchi S, Yamazaki Y et al. Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. Int. J. Tuberc. Lung Dis.9(11), 1281–1287 (2005).
   PubMedGoogle Scholar
• Griffith DE, Brown BA, Girard WM et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis.32(11), 1547–1553 (2001).
   PubMed Web of Science ®Google Scholar
• Tanaka E, Kimoto T, Tsuyuguchi K et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am. J. Respir. Crit. Care Med.160(3), 866–872 (1999).
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Nakajima Y, Takasuna K et al. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur. J. Cardiothorac. Surg.21(2), 314–318 (2002).
   PubMedGoogle Scholar
• Nelson KG, Griffith DE, Brown BA, Wallace RJ Jr. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann. Thorac. Surg.66(2), 325–330 (1998).
   PubMedGoogle Scholar
• Wallace RJ, Jr., Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am. J. Respir. Crit. Care Med.153(6 Pt 1), 1766–1772 (1996).
   PubMed Web of Science ®Google Scholar
• Margolis DA, Iseman MD, Whelan G. High rate of adverse events associated with rifabutin therapy for pulmonary MAC: experience of a large referral center. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, USA October 6–9, (2005).
   Google Scholar
• Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest107(4), 1035–1040 (1995).
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin. Infect. Dis.30(2), 288–292 (2000).
   PubMed Web of Science ®Google Scholar
• Brown BA, Griffith DE, Girard W, Levin J, Wallace RJ Jr. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin. Infect. Dis.24(5), 958–964 (1997).
   PubMedGoogle Scholar
• Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J. Infect. Dis.171(3), 747–750 (1995).
   PubMed Web of Science ®Google Scholar
• Shafran SD, Singer J, Zarowny DP et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J. Infect. Dis.177(1), 252–255 (1998).
   PubMed Web of Science ®Google Scholar
• Langenderfer B. Alternatives to percussion and postural drainage. A review of mucus clearance therapies: percussion and postural drainage, autogenic drainage, positive expiratory pressure, flutter valve, intrapulmonary percussive ventilation, and high-frequency chest compression with the ThAIRapy Vest. J. Cardiopulm. Rehabil.18(4), 283–289 (1998).
   PubMedGoogle Scholar
• Thompson CS, Harrison S, Ashley J, Day K, Smith DL. Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax57(5), 446–448 (2002).
   PubMed Web of Science ®Google Scholar
• Volsko TA, DiFiore J, Chatburn RL. Performance comparison of two oscillating positive expiratory pressure devices: Acapella versus Flutter. Respir. Care48(2), 124–130 (2003).
   PubMedGoogle Scholar
• Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Respir. Crit. Care Med.159(6), 1843–1848 (1999).
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Eberl S, Chan HK, Young IH. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest119(2), 414–421 (2001).
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Gomes K et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology10(1), 46–56 (2005).
   PubMed Web of Science ®Google Scholar
• Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir. Med.99(1), 27–31 (2005).
   PubMed Web of Science ®Google Scholar
• Donaldson SH, Bennett WD, Zeman KL et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med.354(3), 241–250 (2006).
   PubMed Web of Science ®Google Scholar
• Elkins MR, Robinson M, Rose BR et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med.354(3), 229–240 (2006).
   PubMed Web of Science ®Google Scholar
• Beal JE, Olson R, Laubenstein L et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom. Manage.10(2), 89–97 (1995).
   PubMed Web of Science ®Google Scholar
• Beal JE, Olson R, Lefkowitz L et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J. Pain Symptom. Manage.14(1), 7–14 (1997).
   PubMed Web of Science ®Google Scholar
• Pascual LA, Figuls M, Urrutia CG et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J. Pain Symptom. Manage.27(4), 360–369 (2004).
   PubMedGoogle Scholar
• Jatoi A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J. Clin. Oncol.20(2), 567–573 (2002).
   PubMed Web of Science ®Google Scholar
• McKone EF, Tonelli MR, Aitken ML. Adrenal insufficiency and testicular failure secondary to megestrol acetate therapy in a patient with cystic fibrosis. Pediatr. Pulmonol.34(5), 381–383 (2002).
   PubMedGoogle Scholar
• Stockheim JA, Daaboul JJ, Yogev R et al. Adrenal suppression in children with the human immunodeficiency virus treated with megestrol acetate. J. Pediatr.134(3), 368–370 (1999).
   PubMedGoogle Scholar
• Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science307(5707), 223–227 (2005).
   Google Scholar
• Hickey AJ, Lu D, Ashley ED, Stout J. Inhaled azithromycin therapy. J. Aerosol. Med.19(1), 54–60 (2006).
   PubMedGoogle Scholar
• Colin AA. Eradication of mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr. Pulmonol.30(3), 267–268 (2000).
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma A, Zahoor A et al. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother.52(6), 981–986 (2003).
   PubMed Web of Science ®Google Scholar
• British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax56(3), 167–172 (2001).
   PubMed Web of Science ®Google Scholar
• British Thoracic Society. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int. J. Tuberc. Lung Dis.6(7), 628–634 (2002).
   PubMed Web of Science ®Google Scholar